GlycoMimetics, Inc.

As of April 28, 2022, GlycoMimetics, Inc. is considered overvalued with a valuation grade of "does not qualify," reflected by a high Price to Book Value of 3.71, a negative EV to EBIT and EV to EBITDA, and an alarming ROE of -650.50%, despite a remarkable year-to-date stock return of 5096.79%.

As of April 28, 2022, GlycoMimetics, Inc. is considered overvalued with negative financial metrics, including a non-applicable P/E ratio, a Price to Book Value of 3.71, and an ROE of -650.50%, despite a recent volatile stock performance that saw a 6165.36% return over one month.

As of June 6, 2025, the market trend is bearish with moderate strength, indicated by a bearish RSI and a mildly bearish OBV, despite some bullish signals from MACD and daily moving averages.

As of March 2022, the management team of GlycoMimetics, Inc. includes Independent Chairman Mr. Timothy Pearson, President and CEO Ms. Rachel King, and six Independent Directors: Ms. Patricia Andrews, Dr. Mark Goldberg, Mr. Scott Jackson, Mr. Daniel Junius, and Dr. Scott Koenig. This team is responsible for guiding the company's strategic direction and operations.

GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on developing glycomimetic drugs, with a market cap of $8.56 million and a recent net profit loss of $2 million. The company has no dividend yield and significant negative return on equity.

As of Jun 18, GlycoMimetics, Inc. has a market capitalization of 8.56 million, with net sales of 0.00 million and a net profit of -29.48 million over the latest four quarters. The company reported shareholder's funds of 5.31 million and total assets of 11.09 million as of Dec 24.